Elevated Serum Levels of IGF-1 Are Sufficient to Establish Normal Body Size and Skeletal Properties Even in the Absence of Tissue IGF-1 by Elis, Sebastien et al.
Elevated Serum Levels of IGF-1 Are Sufficient to Establish
Normal Body Size and Skeletal Properties Even in the
Absence of Tissue IGF-1
Sebastien Elis,
1 Hayden-William Courtland,
1 Yingjie Wu,
1 Clifford J Rosen,
2 Hui Sun,
1 Karl J Jepsen,
3
Robert J Majeska,
4 and Shoshana Yakar
1
1Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, NY, USA
2Maine Medical Center Research Institute, Scarborough, ME, USA
3Leni and Peter W May Department of Orthopaedics, Mount Sinai School of Medicine, New York, NY, USA
4Department of Biomedical Engineering, City College of New York, New York, NY, USA
ABSTRACT
Use of recombinant insulin-like growth factor 1 (IGF-1) as a treatment for primary IGF-1 deficiency in children has become increasingly
common. When untreated, primary IGF-1 deficiency may lead to a range of metabolic disorders, including lipid abnormalities, insulin
resistance, and decreased bone density. To date, results of this therapy are considered encouraging; however, our understanding of the
role played by IGF-1 during development remains limited. Studies on long-term treatment with recombinant IGF-1 in both children and
animalsarefew.Here,weusedtwonoveltransgenicmousestrainstotestthelong-termeffects ofelevatedcirculatingIGF-1onbodysize
and skeletal development. Overexpression of the rat igf1 transgene in livers of mice with otherwise normal IGF-1 expression (HIT mice)
resulted in approximately threefold increases in serum IGF-1 levels throughout growth, as well as greater body mass and enhanced
skeletal size, architecture, and mechanical properties. When the igf1 transgene was overexpressed in livers of igf1 null mice (KO-HIT), the
comparably elevated serum IGF-1 failed to overcome growth and skeletal deficiencies during neonatal and early postnatal growth.
However, between 4 and 16 weeks of age, increased serum IGF-1 fully compensated for the absence of locally produced IGF-1 because
body weights and lengths of KO-HIT mice became comparable with controls. Furthermore, micro-computed tomography (mCT) analysis
revealed that early deficits in skeletal structure of KO-HIT mice were restored to control levels by adulthood. Our data indicate that in the
absence of tissue igf1 gene expression, maintaining long-term elevations in serum IGF-1 is sufficient to establish normal body size, body
composition, and both skeletal architecture and mechanical function.  2010 American Society for Bone and Mineral Research.
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Introduction
T
he growth hormone (GH)–insulin-like growth factor 1 (IGF-1)
axis is notably complex owing to the number of IGF-1-
binding proteins that modulate its activities,
(1) the ability of GH
and IGF-1 to act individually as well as collectively, and in
particular, the ability of IGF-1 to act via both endocrine and
autocrine/paracrine pathways.
(2–4) As an endocrine agent, IGF-1
is the major circulating hormone produced by the liver,
principally in response to GH; as a paracrine factor, IGF-1 is
produced by a wide range of cell types, where its expression is
regulated not only by GH but also by numerous other local and
systemic agents.
This complexity of the GH–IGF-1 system is especially evident in
its control of skeletal development. Both igf1 null and GH receptor
(ghr) null mice showed reduced bone length, total cross-sectional
bone area, and cortical bone area compared with wild-type
mice,
(5,6) but igf1 null mice exhibited greater impairment in bone
accretion than mice lacking GHR or GH, suggesting GH-
independent IGF-1 effects during postnatal growth. Further, mice
lacking GHR activation (eg, Snell dwarf, Ames dwarf, or ghr null
mice) are indistinguishable from their control littermates up to
3 weeks after birth, but then their relative size decreases to 60% to
50% of controls, confirming the important role of GH in postnatal
longitudinal growth.
(7) On the other hand, the relative size of igf1
null mice is low at birth (60% of controls) and then decreases
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1257progressivelyto30%ofadultcontrolsize,revealingtheimportance
o fI G F - 1i nb o t hp r e -a n dp o s t n a t a lg r o w t h .
(8,9)
IGF-1 regulates the growing skeleton via both endocrine and
autocrine/paracrine pathways. In liver-IGF-1-deficient (LID) mice,
which Exhibit 75% reductions in serum IGF-1 but normal skeletal
IGF-1 expression, serum IGF-1 regulates periosteal bone
growth and determines bone size and bone strength.
(10)
Moreover, we found that decreases in endocrine (serum) IGF-
1 levels impair skeletal development only at the onset of puberty
(beginning after 4 weeks of age, at which time IGF-1 normally
peaks in serum).
(10) We therefore proposed that endocrine IGF-1
is a major determinant of skeletal growth at prepubertal age and
during puberty, whereas autocrine/paracrine IGF-1 regulates
skeletal growth early pre- and postnatally (up to 4 weeks).
During the last decade, it became evident that administration
ofrecombinantIGF-1toGH-resistantpatients(Laron’sdwarfs)
(11–
15) or to ghr null mice
(16) results in increased longitudinal growth,
suggesting that elevated levels of endocrine IGF-1 can stimulate
growth of the prepubertal and adult skeleton, even in states of
diminished autocrine/paracrine IGF-1 action. Here, we sought to
determine whether increased levels of endocrine IGF-1 can
rescue the severe skeletal phenotype of igf1 null mice and at
what time during development this may occur. We performed
longitudinal analyses of three mouse models: (1) control mice,
which express normal levels of tissue and serum IGF-1, (2)
hepaticigf1transgenic(HIT)mice,whichexpressnormallevelsof
tissue IGF-1 but overexpress the rat igf1 transgene in liver and
therefore have increased serum IGF-1 levels, and (3) mice with
the igf1 gene totally ablated but overexpressing the rat igf1
transgene in liver (KO-HIT), therefore exhibiting increased serum
IGF-1 levels in the absence of igf1 gene expression in tissues.
(17)
We found that increased serum IGF-1 levels in HIT mice led to
increased body size and enhancement of skeletal morphologic
parameters and skeletal strength. In contrast, autocrine/para-
crine IGF-1 deficiency in KO-HIT mice hindered early postnatal
skeletal growth despite elevated levels of serum IGF-1. None-
theless, by adulthood, increased serum IGF-1 levels compen-
sated for these deficiencies and even restored skeletal strength
above control levels.
Materials and Methods
Animals
Female HIT and KO-HIT mice (on FVB/N background) were
generated as described previously.
(17) All mice were homo-
zygous forthe igf1 transgene. Femalemice werehoused four per
cage in a clean mouse facility, fed standard mouse chow (Purina
LaboratoryChow5001,PurinaMills,GraySummit,MO)andwater
ad libitum and kept on a 12-hour light/dark cycle. Animal care
andmaintenancewereprovidedthroughtheMountSinaiSchool
of Medicine’s AAALAC Accredited Animal Facility. All procedures
were approved by the Animal Care and Use Committee of the
Mount Sinai School of Medicine.
Serum hormones
Micewerebledthroughthemandibularvein,andserumsamples
were collected between 7 and 9a.m. on a fed state at the
indicated ages. Serum IGF-1 and GH levels were determined
using commercial radioimmunoassays, as described pre-
viously.
(18–20)
Body composition
Body composition (fat and lean mass) was assessed in live
(nonanesthetized) animals using MRI (EchoMRI 3-in-1, Echo
Medical Systems, LLC, Houston, TX). This technique allows highly
precise serial measurements without affecting the subjects
tested. The measurement of each mouse lasts 90 seconds, and
the precision of the measurement is between 0.1 and 0.3 SD.
Micro-Computed tomography (mCT)
Cortical bone morphology at the midfemoral diaphysis and
trabecular bone volume fraction and microarchitecture in the
excised distal femoral metaphysis were assessed as described
previously.
(10) Femurs were reconstructed at an 8.7-mm voxel
resolution. For trabecular bone regions, we assessed the bone
volume fraction (BV/TV, %), trabecular thickness (Tb.Th, mm),
trabecular number (Tb.N), and trabecular spacing (Tb.Sp, mm).
For cortical bone at the femoral midshaft, we measured the
average total cross-sectional area inside the periosteal envelope
(Tt.Ar, mm
2), the cortical bone and medullary area within this
same envelope (Ct.Ar, mm
2, and Ma.Ar, mm
2, respectively), the
relative cortical area (RCA, Ct.Ar/Tt.Ar, %), the average cortical
thickness (Ct.Th, mm), and the polar moment of inertia (Jo).
Robustness was defined as Tt.Ar/Le; a higher ratio denotes
more robust bone. All regions of analysis were standardized
according to anatomic landmarks. Tissue mineral density
(TMD) was defined as the average mineral value of the
bone voxels and expressed in hydroxyapatite density equiva-
lents (HA mg/cm
3).
Mechanical testing
Mouse femurs from 8- and 16-week-old control, HIT, and KO-HIT
mice were tested to failure by four-point bending using a
servohydraulic materials testing system (Instron Corp., Canton,
MA, USA). This test measures whole-bone stiffness, maximum
load, postyield deflection, and work to failure. Femurs were
placed with the anterior surface down on two lower supports.
The two lower and two upper supports were set apart by 6.35
and 2.2mm, respectively. Loading was centered over the
midshaft at a displacement of 0.05mm/s until failure. All
mechanical properties were calculated from the load-displace-
ment curves, as described previously.
(21)
Histomorphometry
Eight-week-old animals were injected with calcein (15mg/kg) 7
and 2 days prior to euthanasia. Femurs were fixed in 10% neutral
buffered formalin, embedded in polymethyl methacrylate
(PMMA), and sectioned (200 mm thickness) at the middiaphysis
using a low-speed diamond-coated wafering saw (Leica,
Bannockburn, IL, USA). Sections were adhered to either glass
or acrylic slides using a nonfluorescing mounting medium. Final
section thicknesses after polishing were between 30 and 40mm.
For determination of osteoclast number, TRAP staining was
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(0.05M of sodium acetate, 0.025M of sodium tartrate, 0.125mg/
mL fast red violet LB salt, and 0.125mg/mL naphtol AS-MX
phosphate) for 180minutes and then washing with water. For
determination of osteoblast number, toluidine blue staining was
performed by incubating slides in a solution of 0.02% toluidine
blue for 30minutes and then washing with water. All
measurements were performed using an OsteoMeasure System
(Osteometrics, Atlanta, GA, USA) in accordance with standard
protocols. Sections were imaged using a digital camera attached
to a visible light/fluorescence microscope (Zeiss Axioplan2, Zeiss
AxioVision, Thornwood, NY, USA).
Statistical analysis
All bone traits, body weight (BW), body composition, serum
hormones, and mCT measurements are presented as mean-
s SEM. One-way analysis of variance (ANOVA) was used to test
for differences among groups at each age (Statview Software
Version 5.0, SAS, Institute, Inc., Cary, NC, USA). If ANOVA revealed
significant effects, the means were compared by Fisher’s test,
considering p<.05 as significant.
Results
Locally produced (autocrine/paracrine) IGF-1 is essential
to establish neonatal and early postnatal body size;
elevated serum IGF-1 compensates for absence of locally
produced IGF-1 only during later postnatal growth
Female HIT and KO-HIT mice were generated as described
previously
(17) using hepatocyte-specific transthyretin (TTR)
promoter driving the rat igf1 transgene (HIT) (all mice were
on FVB/N genetic background, including controls). The TTR
promoter is turned on early during embryogenesis,
(22–25) and
liver RNA isolated from P0 newborns showed high levels of
expression in both HIT and KO-HIT mice (Fig. 1A). Rat igf1
transgene expression in liver led to threefold increases in serum
IGF-1 levels above control mice at 4, 8, and 16 weeks of age in
both HIT and KO-HIT mice (Fig. 1B). It is important to note that
serum IGF-1 levels did not differ between mice that carry one or
two sets of the igf1 transgene, but herein we present only
homozygous transgenic mice. GH levels, assessed by ELISA,
showed no significant difference among the three groups
(control levels ranged from 1.3 to 27.5ng/mL, HIT 0.8 to 41.2ng/
mL, and KO-HIT 1.1 to 73.0ng/mL), as shown previously.
(17)
Female HIT mice with elevated serum IGF-1 in the presence of
normal autocrine/paracrine IGF-1 exhibited greater body
weights (Fig. 1C, D) than controls starting at 1 to 2 weeks of
age: þ17.6% at 2 weeks of age (p<.01), þ10.2% at 4 weeks of
age (p<.05), þ30.4% at 8 weeks of age (p<.0001), and þ19.1%
at 16 weeks of age (p<.0001). In contrast, body weights of KO-
HIT mice with elevated serum IGF-1 but no autocrine/paracrine
IGF-1 were similar to controls from day 1 to 16 weeks of age (at 8
weeks, p¼.0624; at 16 weeks, p¼.1090). Moreover, KO-HIT mice
exhibited an approximately twofold increase in body weight
compared with igf1 null mice throughout growth.
(17) Likewise,
elevations in serum IGF-1 resulted in increases in body length in
HIT mice relative to control mice at 8 and 16 weeks of age
(Fig. 1E). KO-HIT mice, by contrast, wereshorter than controls but
‘‘caught up’’ by 8 weeks of age (Fig. 1E). Despite differences in
body weight, it is important to note that relative fat and lean
mass(normalizedtobodyweights)assessedbyMRIdidnotdiffer
among the groups at any age (Fig. 1F). Together these data
suggested that autocrine/paracrine IGF-1, which is absent in KO-
HIT mice, plays a critical role in establishing body length prior to
4 weeks of age. Elevated serum IGF-1 levels in neonatal KO-HIT
mice failed to overcome this deficiency. On the other hand,
between 4 and 8 weeks, increased serum IGF-1 was able to
compensate for the absence of locally produced IGF-1 because
body lengths of KO-HIT mice became comparable with controls.
When autocrine/paracrine IGF-1 expression is normal,
elevated serum IGF-1 enhances bone structural and
mechanical properties
Female HIT mice with elevated serum IGF-1 showed significant
increases above wild-type control mice in a wide range of bone
structural features. These included longer femora (2.3% to 4.9%)
and greater cross-sectional total area (7.3% to 17.9%), cortical
area (13.9% to 25.4%), cortical thickness (11.5% to 17.2%), and
polar moment of inertia (19.1% to 42.9%) at all ages (Fig. 2).
Cross-sectional areas of HIT femurs also were greater than
controls when normalized to bone length (Tt.Ar/Le), indicating
that elevated serum IGF-1 produced a more robust (less slender)
phenotype (Fig. 2H). Moreover, TMD in HIT mouse femurs was
significantly (3.4%, p<.01) elevated above control mice at 16
weeks. HIT mice also exhibited enhanced trabecular bone
features. mCT analyses of femoral distal metaphyses of 4-, 8-, and
16-week-old female mice revealed that trabecular bone volume/
total volume (BV/TV) peaked at 8 weeks of age for all groups and
thendecreasedbyapproximately24%to32%withage(Fig.3).In
HIT mice, trabecular thickness (Tb.Th) was increased over
controls by 8% at 8 weeks, whereas both trabecular thickness
(13.5%) and TMD (17.9%) were increased at 16 weeks (Fig. 3).
The rapid growth of HIT mice was indicated by an increased
transverse growth rate, which was calculated as the increase in
totalcross-sectionalareabetween4to8and8to16weeksofage
(Fig. 4A). We observed similar increases in cortical bone area
during these two age intervals (Fig. 4B). Consequently, the
enhanced morphologic and compositional phenotypes of HIT
mice led to differences in whole-bone mechanical properties. On
examination by four-point bending tests at the cortical midshaft,
HIT mice showed an increase in maximum load at both 8 and
16 weeks and a significant increase in stiffness by 16 weeks
(Fig. 4C, D), as expected from the increased moment of inertia
and TMD.
To understand the cellular mechanism that led to the HIT
phenotype, we determined serum levels of ostocalcin, a bone-
formation marker, and performed histomorphometric analysis at
the femoral midshaft. Serum osteocalcin at 8 weeks of age
increased significantly in HIT mice compared with controls
(Fig. 4E). Accordingly, we found that in HIT mice, percent labeled
surface at the periosteum increased significantly (Fig. 5).
Additionally, although mineral apposition rate (MAR) did not
differ significantly between control and HIT mice on the
endosteal or periosteal surfaces, periosteal bone formation rate
Elevated Serum Levels of IGF-1 Journal of Bone and Mineral Research 1259(BFR) increased significantly (Fig. 5), which was in accordance
with increased total cross-sectional area, as shown by mCT
analyses.
When autocrine/paracrine IGF-1 expression is absent,
elevated serum IGF-1 fails to prevent early deficiencies
but restores cortical bone morphology and mechanical
properties after puberty
Despite threefold elevation in serum IGF-1 above control levels,
KO-HIT mice exhibited significantly shorter femurs (–4.7%
decrease), reduced Tt.Ar (–14.2% decrease) and cortical area
(Ct.Ar) (–14.3% decrease), and a more slender, less robust
phenotype (reducedTt.Ar/Le) at4weeksofage(Fig.2).However,
between 4 and 8 weeks, KO-HIT mice exhibit marked increase in
growth rate, resulting in increases in Tt.Ar (þ5.4-fold) and Ct.Ar
(þ1.9-fold) above controls (Fig. 4A, B). During pubertal growth
(4 to 8 weeks), KO-HIT mice underwent a marked subperiosteal
expansion such that by 8 weeks their morphologic properties
equaled or surpassed those of controls. In addition, while the
mechanical properties of KO-HIT mice were similar to controls
at 8 weeks, by 16 weeks of age, increases in Ct.Ar and Ct.Th
produced a striking 24.6% increase in maximum load (p<.01)
and a 12.5% increase in stiffness (n.s.) above control values
(Fig. 4C, D). In trabecular bone, none of the morphologic features
examined in KO-HIT mice at either 8 or 16 weeks differed from
controls despite diminished autocrine/paracrine IGF-1 expres-
sion and increased serum IGF-1 levels (Fig. 3).
Unlike HIT mice, serum osteocalcin (Fig. 4E) in KO-HIT mice
decreased when compared with controls. This may indicate that
a secondary factor, regulated by tissue-IGF-1, is required for
enhancement of osteocalcin secretion by osteoblasts. Interest-
Fig. 1. Tissue IGF-1 action is essential for establishment of neonatal and early postnatal body size. The igf1 transgene (RnIGF-1) is expressed in livers (A)
of P0 HIT and KO-HIT newborns, whereas the endogenous mouse igf1 gene (MmIGF-1) is expressed in HIT mice only. Serum levels of IGF-1 (B) measured
from 4 to16 weeksofage.Bodyweightmeasuredfrom1 to 21 dayspostnatally(C), body weightsfrom4 to 16 weeks(D),andlength(nosetoanus)from 4
to 16 weeks of age (E). (F) Relative lean and body fat mass were determined using NMR as described in ‘‘Materials and Methods.’’ Data are presented as
mean SEMofn¼10to15miceineachgroupateachtimepoint.
 p<.05comparingKO-HITmicewithcontrol.
#p<.05comparingHITmicewithcontrol.
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KO-HIT mice, we found that all parameters of bone formation or
resorption on both periosteal and endosteal surfaces in KO-HIT
mice were similar to controls. Moreover, assessment of
osteoblast and osteoclast number and distribution along the
periosteal and endosteal surfaces did not differ among the
groups (Table 1).
Discussion
The results of this study demonstrate clear differences in the
roles played by circulating (liver-derived, endocrine) IGF-1 and
locally produced (autocrine/paracrine) IGF-1 in skeletal devel-
opment. In particular, autocrine/paracrine IGF-1 appears essen-
tial to establish skeletal features during early development
(before 4 weeks) because overexpression of circulating (liver)
IGF-1 in the absence of normal autocrine/paracrine IGF-1
production failed to prevent low body length and early skeletal
deficits. On the other hand, overproduction of circulating IGF-1
by liver fully restored these deficits during late development
such that KO-HIT mice exhibited ‘‘catch-up’’ growth and skeletal
properties at 8 and 16 weeks that were equal to control mice
(Fig. 6). Collectively, the data derived from the skeletal
characterization of the KO-HIT mice suggest that in the absence
oftissue-derived IGF-1and inthe presence of excess serum IGF-1
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Fig. 2. ElevatedserumIGF-1levelsrestorethecorticalenvelopearchitectureintheabsenceoftissueIGF-1action.Corticalbonemorphologywasanalyzed
atthefemurmidshaftby mCT. Bonelength(A), totalcross-sectional area(Tt.Ar)(B),corticalbonearea(Ct.Ar)(C),corticalbonethickness(Ct.Th) (D),marrow
area (Ma.Ar) (E), relative cortical area (RCA¼Ct.Ar/Tt.Ar) (F), polar moment of inertia (G), robustness (Tt.Ar/length) (H), and tissue mineral density (TMD) (I)
were measuredat 4, 8, and 16 weeks of age. Data are presented as mean SEM of n¼10 to 15 mice in each group at each time point.
 p<.05 comparing
KO-HIT mice with control.
#p<.05 comparing HIT mice with control.
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normalized. Also of interest, the effects of endocrine and
autocrine/paracrine IGF-1 were independent of changes in GH,
which remained unaltered from control levels in both HIT and
KO-HIT mice during the entire experiment. This contrasts with
our previous results in LID mice, where ablation of liver IGF-1
production produced a variety of skeletal effects, but these were
superimposed on elevated GH levels.
(10)
The postnatal effects of elevated circulating IGF-1 in HIT and
KO-HIT mice appear consistent with IGF-1 actions in humans,
where fetus serum levels of IGF-1 are relatively low ( 30% of
adult levels),
(26) and a gradual rise is seen during childhood,
with attainment of adult levels at the onset of puberty.
However, during puberty, serum IGF-1 concentrations rise
further by three- to fourfold and then decline gradually
between 20 and 30 years of age. The concentrations of IGF-1
in serum during puberty correlate better with ‘‘bone age’’ than
with chronologic age.
(27) Interestingly, our study shows that
elevations in serum IGF-1 levels during postnatal growth
correlate with enhanced morphologic and mechanical proper-
ties of bone at the end of puberty ( 16 weeks). This
resembles human skeletal growth, where serum IGF-1 elevates
three- to fourfold during puberty and augments bone
growth.
(28)
In a recent study using a knock-in genetic approach,
Stratikopoulos and colleagues showed that endocrine IGF-1
accounts for approximately 30% of overall body growth.
(29) In
that study, knock-in of the igf1 gene exclusively in liver of igf1
null mice partially restored serum IGF-1 levels to 44% of control,
resulting in body weights that were approximately 50% of
controls compared with 30% in igf1 null animals.
(29) Skeletal
growth was not assessed in detail in that study, nor were bone
properties examined; however, based on the relationships
between body weight and bone properties observed in this
study and elsewhere,
(10,30) it appears likely that those adult
skeletons also would have diminished features relative to normal
controls. Thus, while our studies indicate that elevated levels of
circulating IGF-1 can restore normal postnatal skeletal develop-
ment, whether normal IGF-1 levels would suffice has yet to be
established.
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Fig. 3. Elevated serum IGF-1 levels are sufficient to preserve cancellous bone in the absence of tissue IGF-1 action. Cancellous bone morphology was
analyzed at the distal femur by mCT. Bone volume fraction (BV/TV) (A), trabecular thickness (Tb.Th) (B), tissue mineral density (TMD) (C), trabecular number
(Tb.N) (D), and trabecular spacing (Tb.Sp) (E) were measured at 4, 8, and 16 weeks of age. Data are presented as mean SEM of n¼10 to 15 mice in each
group at each time point.
 p<.05 comparing KO-HIT mice with control.
#p<.05 comparing HIT mice with control.
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bones in HIT and KO-HIT mice evolved from 4 to16 weeks
postnatally confirmed previous findings by Jing and colleagues
inwhichoverexpressionofIGF-1inosteoblasts, whichresultedin
concomitant increases in serum IGF-1, led to increases in bone
length, Ct.Th, Ct.Ar, and Tt.Ar.
(31) In our study, we also found that
cortical bone thickness in HIT mice increased gradually from 4 to
16 weeks and was accompanied by decreases in marrow area,
suggesting that both endosteal and periosteal bone apposition
took place. In contrast, despite similar elevations in serum IGF-1
levels,KO-HITmicewereshorterwithasmallerTt.ArthanHITand
control mice at 4 weeks of age. In our previous study, using LID
mice (which Exhibit 75% reductions in serum IGF-1 levels), we
showed that endocrine IGF-1 deficiency resulted in a slender
bone phenotype
(10) affecting mostly cortical bone and with no
adverse effects on cancellous bone. The slender phenotype of
LID mice (reduced Tt.Ar/Le) appeared after 4 weeks of age, when
serum IGF-1 levels peak naturally. In this study, we also found
that endocrine IGF-1 regulates mostly cortical bone architecture
and does not have major effects on cancellous bone. However,
Fig. 4. Elevated serum IGF-1 levels restore bone mechanical properties in the absence of tissue IGF-1 action. Mechanical properties were assessed in
femursby four-pointbending.Stiffness(A), whichindicates resistanceto bending,andmaximal load (B), which indicatesstress at fracture,were measured
at 8 and 16 weeks of age. Data are presented as mean SEM of n¼10 to 15 mice in each group at each time point. Transversal growth rate indicated by
increases in Tt.Ar (C) and Ct.Ar (D) and morphology have been analyzed over two growth periods: from 4 to 8 weeks and from 8 to 16 weeks of age using
the following formula: Growth rate of Ct.Ar between 4 and 8 weeks¼(CtAr8w – CtAr4w)/CtAr4w. Data are presented as mean SEM of n¼10 to 15 mice in
eachgroupover eachperiod of time. Serum osteocalcin levels (E) were measuredat 8 weeks of age.
 p<.05comparingKO-HIT mice with control.
#p<.05
comparing HIT mice with control.
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with elevated serum levels of IGF-1, display a robust bone
phenotype (increased Tt.Ar/Le) that is independent of body
weight(datanotshown)andthatindicesofrobustness(eg,Tt.Ar/
Le, Tt.Ar, and Ct.Ar) were significantly increased at 4 weeks of
age. Interestingly, when tissue IGF-1 action was ablated (KO-HIT),
elevated levels of serum IGF-1 were able to restore linear growth
and skeletal morphology after 4 weeks of age by virtue of
accelerated growth rates. This implies that additional IGF-1-
dependent local factors are necessary to promote skeletal
growth during the neonatal and prepubertal growth phase.
Moreover, despite the fact that skeletal morphology was
restored to control levels as a result of ‘‘catch up’’ growth in
the KO-HIT mice by 8 weeks of age, we did not detect further
increases in Tt.Ar, TMD, or robustness by 16 weeks, suggesting
that both endocrine and autocrine/paracrine functions are
required for establishment of a robust bone phenotype as seen
in the HIT mice. Interestingly, in KO-HIT mice, we found no
changes in marrow area from 4 to 16 weeks of age, whereas
cortical thickness and total area increased owing to periosteal
bone apposition. These data are in accordance with our previous
finding in LID mice (with decreased serum IGF-1 levels), where
periosteal bone apposition was inhibited by 8 weeks of age, and
a compensatory mechanism of marrow in-filling was evident at
32 weeks of age.
(10) Dynamic histomorphometric measurements
of HIT bones showed an increase in bone-formation rate on the
periosteal surface, which was in accordance with increased
serum osteocalcin levels and increased Tt.Ar measured by mCT.
FollowingbonegrowthinHITmicefrom4to16weeksofage,we
found increases in Tt.Ar, Ct.Ar, and Ct.Th, accompanied by
decreases in Mr.Ar. Together, the mCT and histomorphometric
data suggest that processes of bone resorption and apposition
on the periosteal and endosteal surfaces were coupled in HIT
mice. In contrast, in KO-HIT mice, despite similar elevations
in serum IGF-1 levels, osteocalcin levels in serum were reduced,
but all indices of bone formation and resorption, measured by
histomorphometry, were indistinguishable from controls. mCT
analysis showed increases in KO-HIT Ct.Ar during growth,
Fig. 5. Elevated levels of serum IGF-1 increase periosteal bone-formation rate and labeled perimeter only in the presence of local igf1 gene expression.
Cortical bone histomorphometry was assessed from 30-mm plastic sections of the femoral midshaft. Percent labeled surface, percent eroded surface,
mineralapposition rate (MAR),and bone-formation rate (BFR) weremeasuredat the periosteal(A–D) and endosteal(E–H) surfaces. Cross-sectional images
(I) were acquired at  4 magnification and are representative sections of each mouse strain (n¼5 mice per group).
Table 1. Number of Osteoblasts and Osteoclasts Along the
Periosteal and Endosteal Surfaces of the Mid-diaphysis of the
Femur (number of cells/mm)
Endosteum Periosteum
Osteoblasts Osteoclasts Osteoblasts Osteoclasts
Control 8.60 2.22 7.32 2.49 5.85 1.12 3.53 2.17
HIT 6.16 2.12 7.09 1.89 2.69 0.99 2.91 0.63
KO-HIT 4.79 1.29 4.47 1.04 3.17 1.33 6.54 1.22
1264 Journal of Bone and Mineral Research ELIS ET AL.whereas no changes in Mr.Ar were observed. Collectively, these
data may indicate uncoupling of bone resorption and apposition
on the periosteal and endosteal surfaces and suggest that
secondary factor(s), regulated by tissue IGF-1, may be required
for the establishment of bone-growth and bone-drift processes
during normal development. Thus elevations of IGF-1 in serum
can compensate for the absence of tissue IGF-1 during postnatal
growth, but tissue IGF-1 is obligatory for development of the
neonatal skeleton.
IGF-1 plays an important role in bone mineralization, as
evidenced by osteoblast-specific IGF-1 receptor gene ablation
(32)
impairingcouplingofmatrixbiosynthesisandmineralizationand
by mice overexpressing IGF-1 specifically in osteoblasts, which
show increases in BMD as early as 6 weeks of age.
(33) Similarly,
in LID mice, with reduced serum IGF-1 levels, mineralization lag
time increased threefold over controls.
(10) In this study we found
that increases in serum IGF-1 levels lead to increased TMD in HIT
mice and, consequently, greater stiffness and maximum load
values. However, this increase was not detected in the KO-HIT
mice, suggesting that both tissue IGF-1-dependent factors and
serum IGF-1 are required for complete regulation of mineraliza-
tion. Moreover, in the absence of tissue IGF-1, dependence of
mechanical function on morphology may be increased. In
supportofthis,KO-HITmiceexhibitanincreaseinmaximumload
likely owing to increased Ct.Ar, Ct.Th, and RCA because TMD was
not changed.
Long-term treatment (2 to 7 years) with recombinant human
(rh)IGF-1 in prepubertal children
(13–15,34) produces accelerated
linear growth, with the highest growth velocity achieved within
thefirstyearoftreatment.Inafewcases,afast‘‘catchup’’growth
of head circumference was reported as well as progressive
growth of the extremities (hands, feet, chin, and nose). Data
reported at the 2004 Annual Meeting of the Endocrine Society
demonstrated statistically significant increases in both linear
growth and growth rate over an 8-year period in response to
rhIGF-1 therapy. Compared with pretreatment growth patterns,
on average, children gained an additional inch per year for each
year of therapy over the course of 8 years. Our current results are
in agreement with those findings, in that elevated serum IGF-1
levels during development restore linear growth and do not
cause metabolic abnormalities. Moreover, in contrast to human
studies in which bone properties cannot normally be examined
in detail, our findings reveal compartment-specific effects of IGF-
1 on the skeleton (in particular, the cortical shell) and also
demonstrate directly the functional consequences of elevated
serum IGF-1 levels on mechanical properties of bone.
Finally, it is important to note that in recent years IGF-1 has
been linked with several types of malignancy. While cause-effect
relationships have not been established, caution is routinely
exercised when treating children with IGF-1. Our study only
examined mice into adulthood, and while we observed no
obvious pathologic consequences in these animals, longer-term
studies may be needed to address the possibility that high IGF-1
levels during growth affect tumor development or other
pathology later in life.
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